Add BrightSurf on Google Email

Harvard Medical School


Anthrax toxin inhibitor identified

Researchers at Harvard Medical School have identified an anthrax toxin inhibitor that could lead to more effective therapy for the deadly agent. The discovery, made using a 'mixture-based peptide library' technique, reveals new approaches to design better inhibitors that might prove effective in clinical use.

SourceHarvard Medical School·JournalNature Structural & Molecular Biology·DateDec 29, 2003

Patients stop meds when benefit changes

A study by Harvard Medical School found that employees treated for chronic illnesses stop taking necessary medications when benefit changes occur, particularly with substantial co-payment increases. Employers who implemented larger co-payment hikes saw higher rates of medication non-adherence and changes in medication regimens.

SourceHarvard Medical School·JournalNew England Journal of Medicine·DateDec 3, 2003

Dual action anthrax vaccine more effective

A new vaccine targets both the anthrax bacterium and its toxins, demonstrating improved effectiveness in mice tests. The dual-action approach also holds promise as a therapeutic vaccine to help those already infected control the bacteria over time.

SourceHarvard Medical School·JournalProceedings of the National Academy of Sciences·DateSep 1, 2003

Millions of Americans suffer from major depression

A recent study by Harvard Medical School found that millions of Americans suffer from major depressive episodes (MDE), with the majority being severe cases. The researchers measured the severity and duration of depression in over 9,000 Americans and found that only one in five received adequate treatment for their condition.

SourceHarvard Medical School·JournalJAMA·DateJun 17, 2003

Genetic regulator of lifespan identified

The PNC1 protein regulates nicotinamide, a form of vitamin B3, which acts as an inhibitor of Sir2, a founding member of proteins controlling cell survival and lifespan. This discovery suggests that lifespan is controlled by an active genetic program in cells, potentially boostable.

SourceHarvard Medical School·JournalNature·DateMay 7, 2003

Comprehensive set of vision genes discovered: Identification could help in diagnosing and treating blinding diseases

Researchers at Harvard Medical School have identified nearly all the genes responsible for vision in mice, which could lead to new methods for preserving and restoring vision. The discovery provides a genetic data base that can help identify genes mutated in inherited diseases such as retinitis pigmentosa and cone-rod dystrophy.

SourceHarvard Medical School·JournalCell·DateNov 29, 2001

Anthrax immunity gene found in mice

Researchers have identified a genetic variant in mice that provides immunity to anthrax, shedding light on the early stages of infection and potential therapies. The Kif1C protein may play a crucial role in protecting macrophages from self-destruction, and boosting its activity could be an effective approach to treating human anthrax.

SourceHarvard Medical School·JournalCurrent Biology·DateOct 1, 2001

Study indicates alternative medicine here to stay

A new study by Harvard Medical School researchers suggests that complementary and alternative medicine (CAM) is here to stay for the foreseeable future. The use of CAM therapies has steadily increased in popularity since the 1960s, with the largest growth rate occurring during the transition from the 1960s to the 1970s.

SourceHarvard Medical School·JournalAnnals of Internal Medicine·DateAug 20, 2001

Healing the brain from the inside out

Researchers from Children's Hospital and Harvard Medical School have made a groundbreaking discovery that existing brain cells can replenish dead counterparts, potentially treating degenerative brain diseases. The study found that nerve cells in the cerebral cortex can be induced to heal themselves through a process called neuronal rep...

SourceHarvard Medical School·JournalNature·DateJun 20, 2000

Media coverage of new drugs is often misleading

A collaborative study found that media coverage of new medications tends to exaggerate their benefits, ignore their risks, and fail to disclose their costs. Only 40% of news stories citing experts with financial ties to the drug being studied disclosed this potential conflict of interest.

SourceHarvard Medical School·JournalNew England Journal of Medicine·DateMay 31, 2000